NEW INDICATIONS

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

JHOP - June 2021 Vol 11, No 3 - FDA Oncology Update
Download PDF

On March 31, 2021, the FDA accelerated the approval of a new indication for isatuximab-irfc (Sarclisa; sanofi-aventis), a CD38-directed antibody, in combination with carfilzomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy. Isatuximab was initially approved by the FDA in 2020, in combination with pomalidomide and dexamethasone, for adults with relapsed or refractory multiple myeloma who have received ≥2 therapies, including lenalidomide and a proteasome inhibitor.

The FDA approval of isatuximab in combination with carfilzomib and dexamethasone was based on the IKEMA study, a multicenter, multinational, randomized, open-label, 2-arm, phase 3 clinical trial of patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy. The study included 302 patients who were randomized in a 3:2 ratio to isatuximab plus carfilzomib and dexamethasone or to carfilzomib and dexamethasone.

The main efficacy outcome was progression-free survival (PFS). The median PFS was not reached (NR) in the isatuximab plus carfilzomib and dexamethasone arm versus 20.27 months (95% confidence interval, 15.77-NR) with carfilzomib and dexamethasone alone (P = .003), a 45% risk reduction of disease progression or death with the addition of isatuximab.

The most common (≥20%) adverse reactions with the isatuximab-based combination were upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. The most common (≥80%) hematology laboratory abnormalities were decreased hemoglobin, decreased lymphocytes, and decreased platelets.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: